vs

Side-by-side financial comparison of National Energy Services Reunited Corp. (NESR) and PHIBRO ANIMAL HEALTH CORP (PAHC). Click either name above to swap in a different company.

PHIBRO ANIMAL HEALTH CORP is the larger business by last-quarter revenue ($373.9M vs $295.3M, roughly 1.3× National Energy Services Reunited Corp.). PHIBRO ANIMAL HEALTH CORP runs the higher net margin — 7.3% vs 6.0%, a 1.3% gap on every dollar of revenue. On growth, PHIBRO ANIMAL HEALTH CORP posted the faster year-over-year revenue change (20.9% vs -12.2%). PHIBRO ANIMAL HEALTH CORP produced more free cash flow last quarter ($8.3M vs $-34.1M).

National Energy Services Reunited Corp. is a leading integrated oilfield services provider offering a full suite of solutions covering well construction, completion, production, and intervention services for upstream oil and gas operators. Its core markets cover the Middle East, North Africa, and East Asia, serving both national oil companies and international energy clients.

Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...

NESR vs PAHC — Head-to-Head

Bigger by revenue
PAHC
PAHC
1.3× larger
PAHC
$373.9M
$295.3M
NESR
Growing faster (revenue YoY)
PAHC
PAHC
+33.1% gap
PAHC
20.9%
-12.2%
NESR
Higher net margin
PAHC
PAHC
1.3% more per $
PAHC
7.3%
6.0%
NESR
More free cash flow
PAHC
PAHC
$42.3M more FCF
PAHC
$8.3M
$-34.1M
NESR

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
NESR
NESR
PAHC
PAHC
Revenue
$295.3M
$373.9M
Net Profit
$17.7M
$27.5M
Gross Margin
12.0%
35.5%
Operating Margin
6.6%
13.5%
Net Margin
6.0%
7.3%
Revenue YoY
-12.2%
20.9%
Net Profit YoY
-14.0%
762.1%
EPS (diluted)
$0.18
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NESR
NESR
PAHC
PAHC
Q4 25
$373.9M
Q3 25
$295.3M
$363.9M
Q2 25
$327.4M
$378.7M
Q1 25
$303.1M
$347.8M
Q4 24
$309.3M
Q3 24
$336.2M
$260.4M
Q2 24
$325.0M
$273.2M
Q1 24
$263.2M
Net Profit
NESR
NESR
PAHC
PAHC
Q4 25
$27.5M
Q3 25
$17.7M
$26.5M
Q2 25
$15.2M
$17.2M
Q1 25
$10.4M
$20.9M
Q4 24
$3.2M
Q3 24
$20.6M
$7.0M
Q2 24
$18.9M
$752.0K
Q1 24
$8.4M
Gross Margin
NESR
NESR
PAHC
PAHC
Q4 25
35.5%
Q3 25
12.0%
32.9%
Q2 25
13.4%
29.0%
Q1 25
12.4%
30.1%
Q4 24
32.9%
Q3 24
15.9%
32.1%
Q2 24
16.4%
31.9%
Q1 24
30.2%
Operating Margin
NESR
NESR
PAHC
PAHC
Q4 25
13.5%
Q3 25
6.6%
14.1%
Q2 25
8.3%
8.9%
Q1 25
6.9%
9.6%
Q4 24
8.3%
Q3 24
10.5%
6.8%
Q2 24
10.5%
6.7%
Q1 24
7.6%
Net Margin
NESR
NESR
PAHC
PAHC
Q4 25
7.3%
Q3 25
6.0%
7.3%
Q2 25
4.6%
4.5%
Q1 25
3.4%
6.0%
Q4 24
1.0%
Q3 24
6.1%
2.7%
Q2 24
5.8%
0.3%
Q1 24
3.2%
EPS (diluted)
NESR
NESR
PAHC
PAHC
Q4 25
$0.67
Q3 25
$0.18
$0.65
Q2 25
$0.16
$0.43
Q1 25
$0.11
$0.51
Q4 24
$0.08
Q3 24
$0.22
$0.17
Q2 24
$0.20
$0.02
Q1 24
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NESR
NESR
PAHC
PAHC
Cash + ST InvestmentsLiquidity on hand
$69.7M
$74.5M
Total DebtLower is stronger
$274.1M
$624.2M
Stockholders' EquityBook value
$956.7M
$332.4M
Total Assets
$1.8B
$1.4B
Debt / EquityLower = less leverage
0.29×
1.88×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NESR
NESR
PAHC
PAHC
Q4 25
$74.5M
Q3 25
$69.7M
$85.3M
Q2 25
$131.8M
$77.0M
Q1 25
$78.7M
$70.4M
Q4 24
$67.1M
Q3 24
$118.2M
$89.8M
Q2 24
$75.0M
$114.6M
Q1 24
$98.7M
Total Debt
NESR
NESR
PAHC
PAHC
Q4 25
$624.2M
Q3 25
$274.1M
$628.0M
Q2 25
$291.7M
$631.7M
Q1 25
$309.2M
$635.4M
Q4 24
$639.1M
Q3 24
$358.7M
$295.2M
Q2 24
$376.7M
$312.1M
Q1 24
Stockholders' Equity
NESR
NESR
PAHC
PAHC
Q4 25
$332.4M
Q3 25
$956.7M
$311.7M
Q2 25
$936.9M
$285.7M
Q1 25
$920.5M
$266.0M
Q4 24
$246.8M
Q3 24
$873.5M
$258.5M
Q2 24
$851.4M
$256.6M
Q1 24
$270.1M
Total Assets
NESR
NESR
PAHC
PAHC
Q4 25
$1.4B
Q3 25
$1.8B
$1.4B
Q2 25
$1.8B
$1.4B
Q1 25
$1.8B
$1.3B
Q4 24
$1.3B
Q3 24
$1.8B
$966.3M
Q2 24
$1.8B
$982.2M
Q1 24
$979.0M
Debt / Equity
NESR
NESR
PAHC
PAHC
Q4 25
1.88×
Q3 25
0.29×
2.01×
Q2 25
0.31×
2.21×
Q1 25
0.34×
2.39×
Q4 24
2.59×
Q3 24
0.41×
1.14×
Q2 24
0.44×
1.22×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NESR
NESR
PAHC
PAHC
Operating Cash FlowLast quarter
$6.7M
$19.4M
Free Cash FlowOCF − Capex
$-34.1M
$8.3M
FCF MarginFCF / Revenue
-11.5%
2.2%
Capex IntensityCapex / Revenue
13.8%
3.0%
Cash ConversionOCF / Net Profit
0.38×
0.70×
TTM Free Cash FlowTrailing 4 quarters
$68.5M
$47.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NESR
NESR
PAHC
PAHC
Q4 25
$19.4M
Q3 25
$6.7M
$9.3M
Q2 25
$98.5M
$21.3M
Q1 25
$20.5M
$43.2M
Q4 24
$3.1M
Q3 24
$70.8M
$12.6M
Q2 24
$28.4M
Q1 24
$11.4M
Free Cash Flow
NESR
NESR
PAHC
PAHC
Q4 25
$8.3M
Q3 25
$-34.1M
$-4.5M
Q2 25
$68.7M
$8.1M
Q1 25
$-9.6M
$35.4M
Q4 24
$-4.7M
Q3 24
$43.4M
$3.0M
Q2 24
$15.4M
Q1 24
$1.7M
FCF Margin
NESR
NESR
PAHC
PAHC
Q4 25
2.2%
Q3 25
-11.5%
-1.2%
Q2 25
21.0%
2.1%
Q1 25
-3.2%
10.2%
Q4 24
-1.5%
Q3 24
12.9%
1.2%
Q2 24
5.6%
Q1 24
0.6%
Capex Intensity
NESR
NESR
PAHC
PAHC
Q4 25
3.0%
Q3 25
13.8%
3.8%
Q2 25
9.1%
3.5%
Q1 25
9.9%
2.2%
Q4 24
2.5%
Q3 24
8.1%
3.7%
Q2 24
4.8%
Q1 24
3.7%
Cash Conversion
NESR
NESR
PAHC
PAHC
Q4 25
0.70×
Q3 25
0.38×
0.35×
Q2 25
6.48×
1.24×
Q1 25
1.97×
2.07×
Q4 24
0.97×
Q3 24
3.43×
1.81×
Q2 24
37.80×
Q1 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NESR
NESR

Production Services$174.4M59%
Drilling And Evaluation Services$120.9M41%

PAHC
PAHC

Medicated Feed Additives And Others$202.1M54%
Mineral Nutrition$68.9M18%
Nutritional Specialties$50.2M13%
Vaccines$37.6M10%
Performance Products$15.0M4%

Related Comparisons